Thursday, 25 June 2015

One more clinical Meeting

Each year we have the annual meetings of  ECTRIMS/ACTRIMS and then the other big news day is the American Academy of Neurology (AAN) meeting...not to be out done this week, we had the first European Academy of Neurology meeting in Berlin. 

So another opportunity for pharma to break their trial data and a trip for the 25,000 European Neuros footed by Pharma ...Hoorah

Will neuros stop going to the USA for their updates in medicine.

Continuing medical education is a must for Docs 
             See What's Interesting and let us know (CLICK)
                There you can hear about the INSPIRE study
                       and an update on the Biotin MS Trial


  1. Yes i know its not the G INSPIRE but a german trial of the same name.

  2. Let's not forget MS Frontiers next week!

  3. Anything that particularly catches your guys attention?
    The biotin read out is more on the trial they have already completed I believe?
    i have emailed guillaume from Medday who is wanting apply for marker authorisation in eu and U.S. 2016 I think

  4. The impressive results (P1252) using rituximab adds to a growing body of evidence that it is should receive thorough consideration when natalizumab is discontinued. It is a highly effective medicine which should be used more often in MS if NEDA is the goal.
    EAN Poster 1252 Rituximab treatment after natalizumab discontinuation in relapsing-remitting multiple sclerosis (RR-MS) patients with high risk of PML.

    Rituximab Following Natalizumab Withdrawal in Relapsing Remitting Multiple Sclerosis

    Safety, Tolerability, and Efficacy of Rituximab in the Treatment of Multiple Sclerosis: 285 Patients Treated in a Single Center.

  5. Was this presented

    What are the implications for treatment that they are talking about?


Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.